NASDAQ:LONA Athira Pharma (LONA) Stock Price, News & Analysis $7.70 +0.03 (+0.39%) As of 09/3/2026 03:45 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOwnershipSEC Filings About Athira Pharma Stock (NASDAQ:LONA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Athira Pharma alerts:Sign Up Key Stats Today's Range$7.54▼$8.0750-Day Range$6.97▼$9.8052-Week Range$3.52▼$14.21Volume7,646 shsAverage Volume58,160 shsMarket Capitalization$72.30 millionP/E RatioN/ADividend YieldN/APrice Target$17.33Consensus RatingModerate Buy Company Overview Athira Pharma, Inc. is a clinical‐stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease‐modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS). The centerpiece of Athira’s pipeline is fosgonimeton (ATH‐1017), a small‐molecule positive modulator of the HGF/MET system. Fosgonimeton has advanced through Phase 1 and Phase 2 clinical trials, where it has been evaluated for safety, tolerability and preliminary efficacy in patients with mild to moderate Alzheimer’s disease and other forms of cognitive impairment. In addition to ATH‐1017, the company is exploring follow‐on small‐molecule candidates designed to target related pathways and broaden the potential therapeutic impact across multiple neurodegenerative indications. Athira Pharma went public in 2019 and is traded on the Nasdaq under the symbol ATHA. The company conducts clinical studies in the United States and Europe in collaboration with academic research centers and contract research organizations. Leadership has included key figures from both the biotech and neuroscience research communities, with a management team experienced in drug development, clinical operations and regulatory affairs. Athira continues to engage with strategic partners to support its mission of bringing novel, disease‐modifying treatments to patients suffering from progressive neurological disorders. AI Generated. May Contain Errors. Read More Athira Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks59th Percentile Overall ScoreLONA MarketRank™: Athira Pharma scored higher than 59% of companies evaluated by MarketBeat, and ranked 354th out of 913 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingAthira Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.Upside PotentialAthira Pharma has a consensus price target of $17.33, representing about 125.1% upside from its current price of $7.70.Amount of Analyst CoverageAthira Pharma has only been the subject of 3 research reports in the past 90 days.Read more about Athira Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Athira Pharma are expected to grow in the coming year, from ($2.67) to ($2.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Athira Pharma is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Athira Pharma is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAthira Pharma has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.56% of the float of Athira Pharma has been sold short.Short Interest Ratio / Days to CoverAthira Pharma has a short interest ratio ("days to cover") of 3.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Athira Pharma has recently decreased by 4.28%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAthira Pharma does not currently pay a dividend.Dividend GrowthAthira Pharma does not have a long track record of dividend growth. News and Social Media1.3 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 4 news articles for Athira Pharma this week, compared to 1 article on an average week.Search Interest2 people have searched for LONA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows2 people have added Athira Pharma to their MarketBeat watchlist in the last 30 days. Company Ownership1.4 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Athira Pharma insiders have not sold or bought any company stock.Percentage Held by Insiders25.73% of the stock of Athira Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions57.12% of the stock of Athira Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Athira Pharma's insider trading history. Receive LONA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Athira Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LONA Stock News HeadlinesAthira Pharma, Inc. (NASDAQ:LONA) Given Average Rating of "Moderate Buy" by Brokerages3 hours ago | americanbankingnews.comLeonaBio to Participate in Cantor Global Healthcare Conference 2026September 3 at 7:00 AM | globenewswire.comThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying out up to $1,152 a month to regular investors - no mining stocks, no options, no physical metal required. Chief Income Strategist Tim Plaehn calls it a breakthrough strategy that transforms gold's rally into reliable monthly payouts. The next distribution is just days away.September 4 at 1:00 AM | Investors Alley (Ad)Seattle-area biotech led by ex-Athira CEO Leen Kawas raises $35M for hepatitis D drugAugust 31, 2026 | msn.comLeonaBio Reports Second Quarter 2026 Financial Results and Provides Business UpdateAugust 14, 2026 | globenewswire.comLeonaBio to Highlight Lasofoxifene in ER-positive (ER+), HER2-negative, ESR1-mutated Metastatic Breast Cancer at DAVA Oncology's 4th Summit on Breast CancerAugust 12, 2026 | globenewswire.comLeonaBio Presents on ATH-1105 at 5th Annual ALS Drug Development SummitJune 4, 2026 | globenewswire.comLeonaBio to Participate in Upcoming Medical and Industry Meetings in JuneMay 27, 2026 | globenewswire.comSee More Headlines LONA Stock Analysis - Frequently Asked Questions How have LONA shares performed this year? Athira Pharma's stock was trading at $6.55 at the beginning of 2026. Since then, LONA shares have increased by 17.6% and is now trading at $7.70. How were Athira Pharma's earnings last quarter? Athira Pharma, Inc. (NASDAQ:LONA) posted its quarterly earnings data on Friday, August, 14th. The company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.60) by $0.20. When did Athira Pharma's stock split? Shares of Athira Pharma reverse split on Thursday, September 18th 2025.A 1-10 reverse split was announced. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, September 17th 2025. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Athira Pharma? Shares of LONA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Athira Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Athira Pharma investors own include Pfizer (PFE), PayPal (PYPL), Advanced Micro Devices (AMD), Alibaba Group (BABA), Intel (INTC) and Meta Platforms (META). Company Calendar Last Earnings8/14/2026Today9/04/202612th Annual Cantor Fitzgerald Global Healthcare Conference9/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (6m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 LONA's financial health is in the Green zone, according to TradeSmith. LONA has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:LONA Previous SymbolNASDAQ:ATHA CIK1620463 Webathira.com Phone425-620-8501FaxN/AEmployees40Year Founded2011Price Target and Rating Average Price Target for Athira Pharma$17.33 High Price Target$20.00 Low Price Target$15.00 Potential Upside/Downside+125.1%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($4.21) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$105.61 million Net MarginsN/A Pretax MarginN/A Return on Equity-411.58% Return on Assets-225.73% Debt Debt-to-Equity RatioN/A Current Ratio7.01 Quick Ratio7.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.58 per share Price / Book2.15Miscellaneous Outstanding Shares9,390,000Free Float6,977,000Market Cap$72.30 million OptionableNo Data Beta2.05 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:LONA) was last updated on 9/4/2026 by MarketBeat.com Staff. From Our PartnersThe 2026 beginners Guide to Gold IRAsGold trades near record highs while silver just topped $81 an ounce for the first time ever. Thousands of A...Goldco Direct, LLC | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredAre you leaving Social Security money on the table?Most retirement plans still have gaps in them... The quiet ones that don't show up until it's too late to fix....Money Pickle | SponsoredHow Long Does $2.5M Last in Retirement?Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...Paradigm Press | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredBefore Anthropic becomes impossible to ignore...Riot Platforms just struck a 20-year, 191-megawatt data-center agreement tied to Anthropic, reportedly worth 9...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Athira Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Athira Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
